A number of other checkpoint inhibitor-targeting antibodies have also been previously used with cancer vaccines, including α-Tim-3, α-Tim-4, α-OX40 [54] and it is likely that these would also be beneficial if used in combination with our archaeosome-based vaccine. This evidence concerns the gene HAVCR2 and cancer.